TRT for bodybuilding vs. hypogonadism: where the lines blur

What did @tom.oregan actually say?

Honestly? Not much that's checkable. The transcript captured by the platform is garbled audio, something about eyes running away, which suggests a transcription failure rather than actual spoken content. What we do have is the caption, where Tom writes that TRT "can have many benefits" for bodybuilding goals or clinical hypogonadism, and offers the advice that "less is better" and you should "make the most of the lowest dose you can possibly do." He also warns that abuse leads to consequences. That's the factual footprint we're working with.

So this fact-check leans on his written claims, not a clear spoken argument. That's a limitation worth flagging upfront. The caption-based claims are still worth examining because 280,000 people saw them.

Does the science back the 'less is better' principle?

For clinical TRT in men with diagnosed hypogonadism, yes, the evidence broadly supports starting low and titrating carefully. The 2018 American Urological Association guidelines recommend targeting mid-normal physiological testosterone ranges, typically 400 to 700 ng/dL, rather than pushing to the top of the range or beyond. This matters because supraphysiological dosing increases cardiovascular risk.

The landmark TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine) found that testosterone therapy in middle-aged men with hypogonadism and elevated cardiovascular risk did not significantly increase major cardiac events compared to placebo, but that safety signal only holds at replacement doses, not the supra-physiological levels common in bodybuilding. A 2021 systematic review by Bhasin et al. in the Journal of Clinical Endocrinology and Metabolism confirmed dose-dependent adverse effects including erythrocytosis, sleep apnea exacerbation, and testicular suppression. So the "lowest effective dose" framing is medically sound for clinical patients.

What did they get wrong, or right?

Tom gets partial credit for the low-dose framing. In a TRT clinical context, that is defensible advice and lines up with what endocrinologists actually say.

Where this gets shaky is the bodybuilding framing. He mentions bodybuilding goals in the same breath as TRT under physician supervision. These are not the same thing. TRT is a medical intervention for hypogonadism, a condition defined by consistently low testosterone with symptoms. Using testosterone to optimize physique in a eugonadal person is off-label use, carries different risk profiles, and is not what the clinical literature on TRT safety is studying.

Framing supraphysiological bodybuilding use as something that just requires "less is better" discipline understates the actual risks. Exogenous testosterone at any dose suppresses the hypothalamic-pituitary-gonadal axis. Shutdown of endogenous production is not a consequence only of "abuse," it happens at therapeutic doses too. That's a meaningful omission. A 2019 paper by Corona et al. in Sexual Medicine Reviews documented that even standard TRT doses suppress spermatogenesis significantly, which matters for younger men.

What should you actually know?

If you have symptoms of low testosterone, including fatigue, low libido, poor mood, or reduced muscle mass, get bloodwork done. A diagnosis of hypogonadism requires at least two fasting morning total testosterone measurements below 300 ng/dL alongside clinical symptoms, per Endocrine Society guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism).

If you are already in normal testosterone ranges and are considering testosterone because of bodybuilding goals, you are not a TRT candidate. That is a different conversation involving different risks, including permanent suppression of natural testosterone production, polycythemia, cardiovascular strain, and fertility impact.

• TRT requires a licensed prescriber and regular monitoring of hematocrit, PSA, and testosterone levels.
• "Less is better" is correct for clinical TRT but does not make bodybuilding-level use safe.
• Testosterone is a Schedule III controlled substance in the United States. Its use without a prescription is illegal regardless of dose.
• Compounded testosterone products vary in concentration and delivery and are not equivalent to FDA-approved formulations in terms of regulatory oversight.

The bottom line

Tom's caption offers a reasonable harm-reduction nudge buried inside a problematic framing that blurs clinical medicine with physique enhancement. The "less is better" principle is evidence-backed for hypogonadal patients. The implication that bodybuilding goals and physician-supervised TRT sit comfortably side by side is where the messaging gets sloppy. He avoids actively promoting abuse, which is worth noting, but the caption still packages a Schedule III drug as something with "many benefits" for people who want to look better at the gym. That framing deserves more scrutiny than it gets here.